Hyal AT2101: To begin a 120-patient Phase III U.S. trial this month

Hyal Pharmaceutical Corp. (HYALF) Product: Hyal AT2101, 3 percent Diclofenac in 2.5 percent hyaluronic acid gel Indication: Uncontrolled breakthrough pain associated with chronic osteoarthritis Statu...